Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?

ABSTRACT: Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.

SUBMITTER: Fanos V 

PROVIDER: S-EPMC3226612 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature